Editas Medicine stock gained 2.75 percent on October 7, 2026

Published on 10/08/2026 at 03:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Editas Medicine stock reported USD 11.89 million in Q2 revenue on August 5, 2026, up from USD 3.58 million. Six analysts set a USD 5.80 average target.

EDIT, US28106W1036, Illustration mit AI erstellt.

Editas Medicine (ISIN US28106W1036) reported USD 11.89 million in second-quarter revenue for the period ended June 30, 2026, compared with USD 3.58 million a year earlier. The stock was trading at USD 2.81 on Nasdaq on October 7, 2026, up 2.75 percent during the session.

Revenue rises in Q2 2026

According to CEO.CA, collaboration and research and development revenue reached USD 11.9 million in Q2 2026, compared with USD 3.6 million in Q2 2025. The company attributed the increase primarily to deferred revenue recognized after certain BMS collaboration rights expired.

The company posted a net loss of USD 18.2 million, or USD 0.15 per diluted share, for Q2 2026, compared with a net loss of USD 53.2 million, or USD 0.63 per share, in Q2 2025. Research and development expenses rose to USD 20.2 million from USD 16.2 million, while general and administrative expenses fell to USD 11.6 million from USD 12.9 million.

Cash runway supports EDIT-401

Cash and cash equivalents stood at USD 211.6 million on June 30, 2026, compared with USD 146.6 million on December 31, 2025, according to CEO.CA. Editas said the balance could fund operating expenses and capital spending into the second half of 2028.

The cash position gives Editas room to advance EDIT-401, an in vivo CRISPR program designed for hyperlipidemia. The company said in its August 5, 2026, update that it expected a data update in the first quarter of 2027 after advancing the program toward a Phase 1/2 study.

Consensus target stays above price

MarketBeat reported on October 5, 2026, that six analysts gave Editas a Moderate Buy consensus, with five Buy ratings and one Sell rating. The average 12-month target was USD 5.80, putting the October 7 price of USD 2.81 51.55 percent below the consensus target.

The stock's market context remains volatile: its October 7 intraday range was USD 2.66 to USD 2.85, while the 52-week range extended from USD 1.66 to USD 4.54. The distance between the current quote and the yearly high leaves clinical execution and financing discipline as the central valuation questions.

EDIT stock trades at USD 2.81

Editas Medicine was last at USD 2.81 on Nasdaq on October 7, 2026, at 12:35 p.m. ET, with volume of 1,410,000 shares. Its market capitalization was USD 430.5 million on the same date.